Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome

Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome - Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027645

Enrollment

Registered

2017-06-05

Start date

2016-11-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea Syndrome

Interventions

Control group: first night of PSG result Interventions group: second night of PSG result(using with Suvorexant 15mg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who received enough explanation about this study, and provides agreement in the document.

Exclusion criteria

Exclusion criteria: The patient 19 years or younger at the time of the agreement acquisition

Design outcomes

Primary

Measure	Time frame
Change on the PSG data before and after the single using of orexin receptor antagonist Suvorexant 15 mg	—

Countries

Japan

Contacts

Public ContactYuki Mieno

Fujita Health University Respiratory medicine department

mienon@fujita-hu.ac.jp+81-0562-93-9241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026